The U.S. Food and Drug Administration approved Omisirge, a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a...
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy,...
Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq plus Avastin demonstrated a statistically significant...
Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy...
A landmark paper published in The Lancet Neurology journal by leaders of the Parkinson's Progression Markers Initiative (PPMI), the gold-standard Parkinson's biomarker study sponsored by The...
